<PAGE>
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------------------------------
FORM 8-K
-----------------------------------------------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
August 7, 1995 0-16132
-------------------------------------------------- ----------------------
Date of Report (Date of earliest event reported) Commission File Number
CELGENE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 22-2711928
------------------------------------------------ ---------------------
(State or other jurisdiction of incorporation or (I.R.S. Employer
organization) Identification Number)
7 Powder Horn Drive
Warren, New Jersey 07059
-------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(908) 271-1001
-------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
<PAGE>
Item 5. Other Events.
On August 7, 1995, Celgene Corporation (the "Company") issued
a press release announcing that it had completed a $12 million private placement
of convertible debentures. The press release is filed as Exhibit 1 hereto and is
hereby incorporated by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) not applicable
(b) not applicable
(c) Exhibits
(99) Press Release, dated August 7, 1995.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 14, 1995 CELGENE CORPORATION
By: /s/ Richard G. Wright
-------------------------------
Name: Richard G. Wright
Title: Chairman of the Board and
Chief Executive Officer
3
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Description Page
---------- ------------------------------------------------ ------------
<S> <C> <C>
(99) Press Release, dated August 7, 1995. 5
</TABLE>
<PAGE>
EXHIBIT 99
[LETTERHEAD OF CELGENE CORPORATION]
FOR IMMEDIATE RELEASE Contact: Richard G. Wright Thomas Redington
Celgene Corporation Redington, Inc.
(908) 271-4119 (203) 222-7399
(212) 926-1733
CELGENE COMPLETES $12 MILLION PRIVATE PLACEMENT
Warren, NJ August 7, 1995 - Celgene Corporation (NASDAQ: CELG) said it completed
a $12 million private placement of convertible debentures.
Celgene officials said the proceeds will be used to fund Celgene's preclinical
and clinical activities for its immunotherapeutics programs.
The proceeds put proforma cash and marketable securities at $16.0 million as of
June 30, 1995.
Celgene said the convertible debentures and the shares of common stock issuable
upon their conversion have not been registered under the Securities Act of 1933
as amended (the "Act"), and may not be offered or sold in the United States
absent registration under the Act or an applicable exemption from the
registration requirements of the Act.
The company is developing a family of immunotherapeutic compounds for a number
of serious disease states.
Synovir'TM' (thalidomide), Celgene's lead compound, is currently in clinical
trials for cachexia in AIDS and cancer, rheumatoid arthritis and HIV inhibition.
Additionally, Celgene's New Chemical Entities are entering preclinical
evaluation for graft vs. host disease and may also be useful for inflammatory
bowel disease and other autoimmune diseases such as lupus and multiple
sclerosis.
Celgene's chiral business unit supplies value-added drug intermediates to
leading US and international pharmaceutical companies.
Celgene Corporation, headquartered in Warren, NJ, uses proprietary expertise in
small molecule chemistry to serve the pharmaceutical and allied industries.
###
